This oncogene addiction effect was validated in a cohort of pancreatic cancer patients by retrospective studies such that patients with high concentrations of plasma hRNase5/ANG responded well to erlotinib treatment, implying that hRNase5/ANG has potential to serve as a serum biomarker to predict erlotinib response and select pancreatic cancer patients who would be more responsive to EGFR-targeted therapy [46]. The gene discussed is ANG; the disease is pancreatic neoplasm.